European journal of clinical investigation
-
Eur. J. Clin. Invest. · Nov 2020
Observational StudyTicagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS). ⋯ In the setting of ACS, treatment with ticagrelor or prasugrel reduced long-term mortality and 1-year MACE as compared to clopidogrel.
-
Eur. J. Clin. Invest. · Nov 2020
Biological senescence risk score. A practical tool to predict biological senescence status.
Ageing and biological senescence, both related to cardiovascular disease, are mediated by oxidative stress and inflammation. We aim to develop a predictive tool to evaluate the degree of biological senescence in coronary patients. ⋯ These predictive models allow us to calculate the degree of biological senescence in coronary patients, identifying a subgroup of patients at higher risk and who may require more intensive treatment.
-
Eur. J. Clin. Invest. · Nov 2020
Observational StudyBariatric surgery decreases oxidative stress and protein glycosylation in patients with morbid obesity.
There is growing evidence that oxidative stress (OS) is a critical factor linking obesity with its associated comorbidities, such as cardiovascular diseases. ⋯ For the first time, we here demonstrate the relationship between OS parameters and glycoproteins in people with morbid obesity. So glycoproteins could therefore be a good indicator, together with the oxidative state to assess patient prognosis after BS.
-
Eur. J. Clin. Invest. · Nov 2020
The Role of Methylprednisolone on Preventing Disease Progression for Hospitalized Patients with Severe COVID-19.
COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. ⋯ Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.